Grants / Department of Health and Human Services / Centers for Disease Control and Prevention - ERA

RFA-DP-24-081: Effectiveness of Telehealth-Based Programs to Detect Glaucoma Among High-Risk Populations in Community Health Settings

Closed Closed March 22, 2024 Opportunity RFA-DP-24-081 ☆ Save

This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2023.

• Award ceiling$950,000
• Total funding$15.0 million
• Expected awards5
• Cost sharingNot required
• Funding typeCooperative Agreement

Key dates

Who can apply

This opportunity was open to any type of organization.

This is a new, competitive NOFO. Prior agreements, funding, collaborations, and other arrangements with CDC are not evidence of eligibility for this NOFO.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Past Chronic Diseases: Research, Control, and Prevention awards averaged $651,162; this notice allows up to $950,000 per award.
• Most of the program's money (35% over five years) went to nonprofits.
• No cost sharing or match is required.

What the grant funds

Amendment III February 16, 2024Extended deadline, increased eligibility for Component B applicants, reduced description of research plan for Component B, per below. PRE-APPLICATION WEBINAR UPDATE The pre-application informational webinar will be held January 9, 2024 at 1:00 - 2:00 PM. Pre-registration is not required. Meeting URL: https://cdc.zoomgov.com/j/1618519033?pwd=UEN5WDFncGEvbHBNcXU4QmZFZHQrUT09&from=addon. Meeting ID: 161 851 9033. Passcode: 161 851 9033DESCRIPTION - The purpose of this notice of funding opportunity is to investigate the feasibility, effectiveness, and cost-effectiveness of high-quality and innovative public health interventions to improve glaucoma detection and management among high-risk populations within community-based health care delivery settings. This NOFO has two components. Component A: Comparative effectiveness trials of community-based interventions in high-risk populations in diverse locations. Communities include populations living with undiagnosed eye diseases due to lack of access, resources, vision specialists, etc. Component B: A coordinating center to harmonize data collection and analysis, and logistic and communication support to enhance the efficiency and productivity for component A. Glaucoma is one of the leading causes of irreversible blindness in the United States, and the leading cause of blindness among African Americans. Of an estimated 2.7 million people with glaucoma, 50% of them are unaware of their condition. This NOFO focuses on people at high-risk for glaucoma and does not include broad general screening programs. CDC intends to further research by funding projects with strategies that are cost-effective, comprehensive, and include allied health care professionals (e.g. community healthcare workers, ophthalmic technicians, navigators); mobilize community partners and resources; use advanced technological approaches; demonstrate potential for adoption into real-world clinical practice; and have the greatest potential to affect population health, public policy, and implementation.

Category: Health.

Applying now

This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.